Investors aiming to benefit from large price gains frequently use a two-part method, combining the future-oriented study of company fundamentals with the timing signals from chart analysis. One specific tactic looks for solid growth stocks that are also showing encouraging technical breakout formations. The logic is clear: find firms with sound core business performance and rising earnings, then look for good times to buy when the stock's price movement indicates a possible conclusion to a sideways period and the start of a fresh rising trend. This tactic tries to match a company's business momentum with a positive change in market psychology, as seen on its price chart.
BOSTON SCIENTIFIC CORP (NYSE:BSX) is a leader in medical technology, creating and producing devices for many interventional procedures within its MedSurg and Cardiovascular units. The firm's commitment to minimally-invasive methods places it inside big and increasing worldwide healthcare sectors, an important qualitative element for continued expansion.
Fundamental Strength: The Source for Expansion
The center of the growth investment case for Boston Scientific is found in its convincing fundamental picture. As detailed in a fundamental analysis report, the company receives a high total score, supported by outstanding profitability and firm growth measures. For a growth plan, these are vital parts, as they show the firm's capacity to grow its earnings effectively.
-
Profitability Leader: BSX gets a 9 out of 10 for profitability. Main advantages consist of:
- A Return on Equity of 11.96%, which is higher than 87% of similar healthcare equipment companies.
- Firm and improving margins, with a Profit Margin of 14.44% (superior to 90% of the industry) and an Operating Margin of 19.92%.
- Steadily positive earnings and operating cash flow for the last five years.
-
Confirmed and Expected Growth: The company's growth score of 7 is backed by notable past results and optimistic future projections.
- In the last year, Earnings Per Share (EPS) increased by 21.5% and Revenue rose by 19.9%.
- Typically, EPS has increased by 26% each year over recent periods.
- For the future, experts project EPS growth of 13.1% and Revenue growth of 10.5% per year.
-
Fair Valuation Considering Circumstances: While the P/E ratio seems high by itself, the valuation score of 5 shows a more detailed view. BSX is priced below numerous industry competitors, and its very good profitability and growth outlook support its present multiple. This fits a growth investment style, where investors frequently agree to higher valuations for firms showing better expansion measures.
Technical Picture: A Formation with Possibility
While the fundamentals give the "reason," the chart study gives clues about the "timing." Even with a difficult overall market direction, Boston Scientific's price chart is displaying signals of a possible change from its recent decline, which is exactly what the screening process tries to find. The technical analysis report points out a notable formation chance.
The stock's technical score is now low, mirroring its results over the past year. However, the report gives a high formation rating of 8, stating that "prices have been consolidating lately and the volatility has been reduced." This time of consolidation, after a notable drop, can sometimes come before a new price move.
- Important Support and Resistance: The study finds a defined support area between $68.15 and $69.13, created by several trend lines. After checking this zone, the stock has started to level out.
- Breakout Chance: The report says, "There is very little resistance above the current price." This is a key part for a breakout formation, implying that if buying interest grows and the stock can move above the recent sideways range, it might encounter little nearby selling pressure on its path to test higher price ceilings.
- Market Environment: It is essential to recognize that both the short and long-term directions for the S&P 500 are also negative, which introduces broader market challenges. Still, the screening tactic is made to find specific stocks that could be building positive formations before or despite a softer market.
Why This Pairing is Significant
The meeting point of firm fundamentals and a helpful technical formation is the tactic's central idea. Boston Scientific's fundamental soundness, its excellent profitability, steady cash flow, and high growth, gives the base-level assurance that the company is performing effectively. This lowers the chance that a possible price breakout would be founded only on market sentiment.
The technical formation then supplies a strategic entry plan. The consolidation close to a set support level, combined with lower volatility and an absence of nearby resistance, makes a situation where the potential risk versus reward can be more plainly outlined. For a growth investor, this formation hints the stock may be finishing a pullback period and getting ready for its next advance, powered by its core business momentum.
Finding Other Chances
Boston Scientific offers an example of how fundamental expansion and technical formations can come together. For investors wanting to use this paired study method to discover other possible chances, a preset screen exists.
You can locate more stocks that match this "Strong Growth Stocks with good Technical Setup Ratings" standard by using this predefined stock screener.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, a recommendation, or an offer or solicitation to buy or sell any securities. The analysis is based on data and reports provided by third parties. Investing involves risk, including the potential loss of principal. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.